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Background:  Although many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of common-
ly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated. 
Methods:  We evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naïve type 2 dia-
betes mellitus patients in a 48-week, double-blind, randomized controlled study that included 349 Korean patients. Our primary 
goal was to determine the change in HbA1c levels from baseline to end point. Our secondary goal was to evaluate changes in 
fasting plasma glucose (FPG) levels, body weight, frequency of adverse events, and the proportion of participants achieving tar-
get HbA1c levels.
Results:  HbA1c levels decreased from 7.8% to 6.9% in the glimepiride group (P<0.001), from 7.9% to 7.0% in the metformin 
group (P<0.001), and from 7.8% to 7.0% (P<0.001) in the rosiglitazone group. Glimepiride and rosiglitazone significantly in-
creased body weight and metformin reduced body weight during the study period. Symptomatic hypoglycemia was more frequent 
in the glimepiride group and diarrhea was more frequent in the metformin group. 
Conclusion:  The efficacy of glimepiride, metformin, and rosiglitazone as antidiabetic monotherapies in drug-naïve Korean type 
2 diabetic patients was similar in the three groups, with no statistical difference. This study is the first randomized controlled trial 
to evaluate the efficacy of commonly-used oral hypoglycemic agents in Korean type 2 diabetic patients. An additional subgroup 
analysis is recommended to obtain more detailed information.
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INTRODUCTION
Type 2 diabetes mellitus is a chronic disease characterized by 
increased insulin resistance, defective β-cell function, and in-
creased hepatic gluconeogenesis [1]. The proportion of patients 
with type 2 diabetes has been consistently increasing world-
wide, and recent increases are remarkable in Asia, including 
Korea [2,3]. Because the increasing burden of diabetes causes 
substantial financial loss resulting from increased health care 
expenditures [4], type 2 diabetes is not a personal disease, but 
is an important national public health problem. 
  For glycemic control, life style interventions with metformin 
are recommended as an initial treatment regimen in a consen-
sus statement from the American Diabetes Association [5]. 
And there have been many clinical trials in Western countries 
on the selection of an optimal oral hypoglycemic agent for ini-
tial treatment [6-8]. In Japan, Yamanouchi et al. [9] established 
that several commonly-used oral hypoglycemic agents were 
equally effective in newly-diagnosed type 2 diabetic patients. 
However, the doses of each drug were completely different from 
the usual prescription dosage in Korea, which makes it hard to 
translate those data into clinical practice in Korea. Furthermore, 
there has been no head-to-head comparison in a randomized 
controlled trial to prove the efficacy and safety of antidiabetic 
agents for Korean type 2 diabetic patients. 
  This study was designed to evaluate glycemic control efficacy 
in Korean drug-naïve type 2 diabetic patients receiving mono-
therapy with a sulfonylurea (glimepiride), a biguanide (met-
formin), or a thiazolidinedione (rosiglitazone). 
METHODS
Study design
This study, called the Practical Evidence of Antidiabetic Mono-
therapy Study (PEAM), consisted of a multicenter, random-
ized, double-blind trial performed in 15 centers in Korea. Be-
tween February 2007 and December 2008, 435 patients who 
had not received previous pharmacologic treatment for type 2 
diabetes mellitus were screened and 349 patients were random-
ized to one of three treatment groups. We assigned 118 patients 
to the glimepiride group, 114 patients to the metformin group, 
and 117 patients to the rosiglitazone group (Fig. 1). After a 
4-week life style intervention, the study drugs were prescribed 
to each patient. During the lifestyle intervention period, we 
provided individualized education to each study subject, ac-
cording to current, recommended guidelines for medical nu-
tritional treatment [10]. We also recommended that each sub-
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Fig. 1.  Enrollment and study outcomes. The total number of patients assigned to the three treatment groups was 349. A total of 
36 patients left the glimepiride group, 43 left the metformin group, and 43 left the rosiglitazone group during the study period.Yoon KH, et al.
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sity aerobic physical activity, provided exercise was not contra-
indicated [10]. Trained dietitians or diabetic nurse specialists 
provided the education and made these recommendations; 
however, we did not later verify whether the subjects had fol-
lowed these recommendations appropriately. 
  Participants were examined every 8 weeks for 48 weeks from 
the start of the randomization period. According to the results 
of HbA1c (<6.5% or ≥6.5%) and drug tolerability check that 
was performed at each visit, we performed scheduled up-titra-
tion of the study drugs (Table 1A). Fasting plasma glucose lev-
els (FPG), HbA1c concentrations, medication compliance, and 
a physical examination, including taking vital signs and body 
weight (BW), were assessed or performed at every visit. To 
evaluate the study participants’ medication compliance indi-
rectly, we checked the number of remaining doses at each visit. 
The ratio of the remaining number of doses at the present visit 
to the number of doses prescribed at the previous visit was cal-
culated. Subjects with a ratio greater than 30% were excluded 
in the outcome analysis, since their compliance rate was pre-
sumed to be less than 70%. At the outset of randomization and 
after 48 weeks, we performed a 75 g oral glucose tolerance test. 
Anthropometric characteristics, demographic characteristics, 
electrocardiogram, lipid profiles, complete blood counts (CBC), 
aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), blood urea nitrogen (BUN), and creatinine were evalu-
ated. All adverse events were recorded and judged for severity 
and possible relationship to study medications. The study pro-
tocol was approved by the Institutional Review Board at each 
center and all participants provided written informed consent. 
Study participants
Eligible study participants were between the ages of 30 and 65 
years, with HbA1c levels ranging from 6.5% to 9.5%. None of 
the subjects had ever taken an oral hypoglycemic agent. Glu-
cocorticoid users, pregnant women, patients who had clinical-
ly significant liver disease (AST, ALT>2.5 x upper normal lim-
it), significant renal disease (serum creatinine>1.5 mg/dL in 
men,>1.4 mg/dL in women), a history of lactic acidosis, a his-
tory of unstable angina or severe angina pectoris, a history of 
or treatment for congestive heart failure, or contraindications 
to metformin or sulfonylurea treatment were excluded. 
Goal assessment
The primary goal of this study was to determine changes in 
HbA1c levels from baseline (randomization) to end point. The 
secondary goals were to determine changes in FPG, body 
Table 1.  Study design
(A) Dose titration schedules for study drugs
Glimepiride (2 mg/T) Metformin (500 mg/T) Rosiglitazone (4 mg/T)
AM PM AM PM AM PM
Level 1  2 mg 500 mg 4 mg
Level 2  2 mg 2 mg 500 mg 500 mg 4 mg
Level 3  4 mg 2 mg 1,000 mg 500 mg 4 mg 4 mg
Level 4  4 mg 4 mg 1,000 mg 1,000 mg 4 mg 4 mg
(B) Drug level at each visit
Glimepiride Metformin Rosiglitazone
L1 L2 L3 L4 L1 L2 L3 L4 L1 L2 L3 L4
V1  118 (100) 114 (100) 117 (100)
V2  73 (61.9) 45 (38.1) 46 (40.4) 68 (59.6) 44 (38.6) 73 (61.4)
V3  62 (52.5) 31 (26.3) 25 (21.2) 40 (35.1) 32 (28.1) 42 (36.8) 41 (35.0) 33 (28.2) 43 (36.8)
V4  59 (50.0) 24 (20.3) 17 (14.4) 18 (15.3) 36 (31.6) 28 (24.5) 31 (27.2) 19 (16.7) 39 (33.3) 29 (24.8) 18 (15.4) 31 (26.5)
V5  57 (48.3) 18 (15.3) 17 (14.4) 26 (22.0) 36 (31.6) 23 (20.2) 26 (22.8) 29 (25.4) 36 (30.8) 28 (23.9) 16 (13.7) 37 (31.6)
V6  55 (46.6) 20 (16.9) 8 (6.8) 35 (29.7) 35 (30.7) 22 (19.3) 25 (21.9) 32 (28.1) 34 (29.1) 25 (21.3) 16 (13.7) 42 (35.9)
Values are presented as number (%).
T, tablet; L, level; V, visit.The efficacy of antidiabetic monotherapy in Korean
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weight, and the numbers of subjects achieving target HbA1c 
levels (<6.5%). 
  We evaluated differences in all adverse events for the study 
populations. Hypoglycemia was defined as the presence of typ-
ical adrenergic or neuroglycopenic symptoms and signs, re-
gardless of the data for self-monitoring of blood glucose. Ede-
ma was defined when the subjects had any signs of fluid reten-
tion upon physical examination, or complained of systemic 
edema. 
  At baseline, 24 weeks, and 48 weeks, HbA1c levels were 
measured using high-performance liquid chromatography 
and FPG was determined using a hexokinase method in a cen-
tral laboratory (Samkwang Medical Laboratories, Seoul, Ko-
rea). Levels of FPG and HbA1c in the other follow-up visits, 
and lipid levels, were determined using standard assays in each 
local laboratory. 
Statistical analysis
Originally, we calculated a need to enroll 540 study participants 
to obtain 80% statistical power at a significance level of P=0.05, 
assuming a 20% attrition rate in each study group. At the end 
of the study, the overall attrition rate was 34.9%, with a total of 
349 randomized subjects. We used an intention-to-treat analy-
sis method in analyzing our data. The last observation carried 
forward (LOCF) method was used to fill in missing values at a 
later point in the study. Using per protocol analysis, we includ-
ed, 82 subjects in the glimepiride group, 71 subjects in the met-
formin group, and 74 subjects in the rosiglitazone groups in 
Table 2.  Baseline characteristics
Variable  Total (n=349) Glmepiride (n=118) Metformin (n=114) Rosiglitazone (n=117) P value
Demographic characteristics 
Age, yr  50.9±8.5 50.8±8.9 51.8±8.5 50.1±8.2 0.23
Males, n (%)  193 (55.30) 66 (55.93) 66 (57.89) 61 (52.14) 0.67
Anthropometric characteristics 
Weight, kg  68.7±11.4 67.9±10.9 68.9±11.1 69.1±12. 1 0.69
BMI, kg/m
2  25.6±3.2 25.5±3.1 25.7±3.2 25.8±3.3 0.63
Waist circumference, cm  87.6±7.9 87.0±7.8 88.7±7.2 87.6±7.9 0.18
Hip circumference, cm  97.1±6.3 96.2±5.6 97.5±6.1 97.1±6.3 0.21
Waist-to-hip ratio  0.90±0.05 0.91±0.05 0.91±0.05 0.89±0.05 0.01
Blood pressure 
Systolic, mm Hg  127.2±13.2 126.3±12.8 128.2±12.4 127.0±14.4 0.62
Diastolic, mm Hg  78.9±9.4 78.4±8.7 79.8±8.6 78.8±10.7 0.48
Antihypertensive therapy, n (%)  102 (29.23) 34 (28.81) 33 (28.95) 35 (29.91) 0.98
Lipid-lowering therapy, n (%)  99 (28.37) 35 (29.66) 33 (28.95) 31 (26.50) 0.85
Metabolic characteristics 
FBS, mg/dL  146.6±32.0 145.0±32.0 151.0±32.4 144.1±31.5 0.10
HbA1c, %  7.8±0.8 7.8±0.8 7.9±0.8 7.8±0.8 0.29
Total cholesterol, mg/dL  189.1±37.5 190.2±41.3 186.8±34.3 190.4±36.7 0.72
Triglyceride, mg/dL
a  134.0±108.0 127.0±114.0 144.0±99.0 141.0±119.0 0.69
b
HDL-C, mg/dL
a  45.0±13.0 45.0±12.0 43.0±13.0 47.0±14.0 0.47
b
LDL-C, mg/dL  109.2±37.0 110.9±42.0 106.0±33.7 110.4±34.6 0.54
TC/HDL ratio
a  4.16±1.62 4.03±1.61 4.18±1.52 4.24±1.80 0.88
b
TG/HDL ratio
a  2.87±2.96 2.85±2.79 3.18±2.89 2.79±3.31 0.59
b
Data are presented as mean±standard deviation, except where variable is marked with an symbol
 a. 
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride. 
aData are presented as median±interquartile range, 
bKruskal-Wallis test was used for nonparametric statistical analysis and ANOVA test for 
parametric analysis.Yoon KH, et al.
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our analysis (data not shown here).
  Results are described as mean±standard deviation or 
median±interquartile range. For comparisons of data among 
the three treatment groups, a repeated measured ANOVA test 
was used. For nonparametric statistical analysis, the Kruskal-
Wallis test was used. Wilcoxon’s signed rank test was used for 
comparison of pre- and post-treatment values. For analysis of 
differences in the frequency of adverse events, the chi-square 
test and Fisher’s exact test were used. Statistical analyses were 
performed using SAS version 9.1.3 (SAS Institute, Cary, NC, 
USA). Differences among groups with a P<0.05 were consid-
ered statistically significant. 
RESULTS
Baseline and follow-up characteristics 
The subjects’ baseline characteristics are described in Table 2. 
All variables in baseline characteristics were measured at the 
randomization point. There was no significant difference in 
HbA1c levels, body weight, blood pressure, and lipid profiles 
between the screening visit and the randomization visit (data 
from the screening period not shown here). 
  The mean age of the total study population was 50.9 years, 
the mean HbA1c level was 7.8%, and the mean body mass in-
dex (BMI) was 25.6 kg/m
2. No significant difference was ob-
served in baseline demographics, anthropometrics and meta-
bolic characteristics among the three groups after randomiza-
tion. Medication compliance was not different in the three 
groups. The proportion of participants who completed the study 
was 69.4% in the glimepiride group, 62.3% in the metformin 
group, and 63.2% in the rosiglitazone group. The number of 
study participants at each drug dosage level is described in Ta-
ble 1B.
Primary outcome
HbA1c levels decreased from 7.8% to 6.9% in the glimepiride 
group (P<0.001), from 7.9% to 7.0% in the metformin group 
(P<0.001), and from 7.8% to 7.0% (P<0.001) in the rosigli-
tazone group (Fig. 2). Differences in HbA1c levels from ran-
domization to the end point were -0.89±0.76% in the glimepiri-
de group, -0.92±0.96% in the metformin group, and -0.82± 
0.79% in the rosiglitazone group. There was no significant dif-
ference in the HbA1c levels, or in the changes in HbA1c levels, 
between the three groups (P=0.62) (Fig. 3A).
Secondary outcome
Levels of FPG decreased from 145.0±32.0 mg/dL to 128.1± 
27.9 mg/dL in the glimepiride group (P<0.001), from 151.0±
32.4 mg/dL to 130.8±25.8 mg/dL in the metformin group 
(P<0.001), and from 144.1±31.5 mg/dL to 128.6±35.2 mg/dL 
in the rosiglitazone group (P<0.001). Among the three study 
groups, levels of FPG at baseline and the end point were statis-
tically different (P=0.52) (Fig. 3B). 
  Over the study period, significant weight gain was observed 
in the glimepiride group (ΔBW=1.4 kg, ΔBMI=0.54 kg/m
2). 
In the rosiglitazone group, mean weight increased continu-
ously (ΔBW=1.5 kg, ΔBMI=0.63 kg/m
2); however there was 
significant weight reduction in the metformin group (ΔBW=
-1.1 kg, ΔBMI=-0.44 kg/m
2) (Fig. 3C).
  Study participants achieving target HbA1c levels of less than 
6.5% were 36.44% (43 subjects) of the 118 members of the 
glimepiride group, 24.56% (28 subjects) of the 114 members 
of the metformin group, and 32.48% (38 subjects) in the 117 
members of the rosiglitazone group, without significant differ-
ences among the three groups (P=0.14). Those with HbA1c 
level less than 7.0% were 65.25% (77 subjects) of the glimepiri-
de group, 58.77% (67 subjects) of the metformin group, and 
58.97% (69 subjects) of the rosiglitazone group, with no signif-
icant differences among the three groups (P=0.51) (Fig. 4).
   Glimepiride  Metformin  Rosiglitazone
   -0.89±0.76  -0.92±0.96  -0.82±0.79



















Fig. 2.  Changes in HbA1c from baseline to end point. The 
black bar indicates the HbA1c level at baseline and gray bar at 
end point. Bars represent mean+standard deviation. 
aSignifi-
cant differences between HbA1c at 0 week and 48 weeks (P 
value<0.001). Repeated measured ANOVA test was used for 
statistical analysis. Between the three groups, HbA1c levels 
and changes were not statistically different (P value=0.62). 
∆HbA1c Mean doses at end point.The efficacy of antidiabetic monotherapy in Korean
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Adverse events
Symptomatic hypoglycemia was more frequent in the glimepiri-
de group (19.49% in glimepiride group vs. 3.51% in metformin 
group and 6.84% in rosiglitazone group). Diarrhea was more 
frequent in the metformin group (3.39% of glimepiride group 
vs. 8.77% of metformin group and 1.71% of rosiglitazone 
group). Subjective edema as reported by study participants was 
more frequent in the glimepiride and rosiglitazone groups com-
pared to the metformin group (6.78% of glimepiride group vs. 
0.88% of metformin group and 7.69% of rosiglitazone group) 
(Table 3). Other adverse events, including abdominal discom-
fort, elevated liver enzymes and chest discomfort or dyspnea 
were not different in the three study populations. 
DISCUSSION
The three study drugs similarly decreased HbA1c levels by 0.8-
0.9% by the end of the study. In many previous placebo-con-
trolled trials, glimepiride, metformin, and rosiglitazone lowered 
HbA1c levels by about 1.0-1.5% [11-13]. The differences be-
tween our results and previous studies might be influenced by 
baseline HbA1c levels, BMI, and prescribed doses of the study 
drugs. Previous reports in western countries noted participant 
Fig. 4.  Proportion of patients achieving target HbA1c levels. 
Black bar indicates the proportion of patients achieving 
HbA1c levels less than 7.0% and white bar less than 6.5%. The 
χ
2 test was used for comparison of differences in the three 
groups.
  Glimepiride  Metformin  Rosiglitazone

























































Fig. 3.  Changes in HbA1c (A), fasting plasma glucose (FPG) 
(B), and body weight (C) over time, by treatment group. All 
panels, data are presented as mean±standard error of mean. 
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baseline HbA1c levels 8.5-10% and BMIs of 26-30 kg/m
2 [12,
13], whereas our study participants had HbA1c levels and BMIs 
of 7.8% and 25 kg/m
2, respectively. We infer these different re-
sults may be due to our study population having relatively 
mild hyperglycemia and lower BMIs. 
  At the end of the study, the attrition rate was higher than 
expected (34.9% vs. 20.0%). Therefore, the reliability of our 
trial was lower than originally estimated at the point of study 
design.
  The fastest response of HbA1c and FPG to the study drugs 
was observed in study participants receiving glimepiride in 
the first 24 weeks. This slower action in reducing blood glu-
cose levels using metformin and rosiglitazone, as compared to 
glimepiride, is similar to a previous report [14]. The maximum 
hypoglycemic effect was seen at 32 weeks in the glimepiride 
and rosiglitazone groups and at 40 weeks in the metformin 
group; therefore, an observational period at least 6 to 8 months 
appears to be needed to judge whether a patient is responding 
to a specific oral antihyperglycemic drug. 
  Although about 60% of the study participants reached a tar-
get HbA1c level of less than 7.0%, the rest of the study partici-
pants remained in an inadequate glycemic control state. And 
only about 30% of the subjects reached a target HbA1c less than 
6.5%. To improve the state of patients’ glycemic control, more 










Edema  9 (7.69) 8 (6.78) 1 (0.88) 0.04
b,c
Elevated liver 
   enzymes 
1 (0.85) 5 (4.24) 0 (0.00) 0.05
Symptomatic 
   hypoglycemia 
8 (6.84) 23 (19.49) 4 (3.51) 0.00
a,b
Abdominal 
   discomfort & 
   pain including 
   nausea, vomiting 
15 (12.82) 10 (8.47) 10 (8.77) 0.47
Diarrhea  2 (1.71) 4 (3.39) 10 (8.77) 0.03
b,c
Chest discomfort 
   & dyspnea 
3 (2.56) 3 (2.54) 7 (6.14) 0.28
Total  38 (32.48) 53 (44.92) 32 (28.07)
Data are presented as number (%).
a, 
b, and 
c indicate significant difference between two groups. 
aglimepiride vs. rosiglitazone, 
bglimepiride vs. metformin, 
crosigli-
tazone vs. metformin. χ
2 test and Fisher’s exact test were used for 
comparison of differences in the three groups.
active treatment should be performed and additional studies 
and analyses are needed to elucidate several factors influenc-
ing the level of glycemic control.
  Whereas metformin does not cause weight gain and may 
induce modest weight loss in type 2 diabetic patients, glimepiri-
de and rosiglitazone generally result in weight gain [15-17]. In 
this study, metformin induced significant weight loss, while 
glimepiride and rosiglitazone induced significant weight gain 
in Korean type 2 diabetic patients. This suggests a useful and 
beneficial health effect to using metformin for obese or over-
weight Korean diabetic patients. 
  As in previous studies [18], the most common side effect was 
symptomatic hypoglycemia in the glimepiride group. Although 
metformin and rosiglitazone are not known to induce hypo-
glycemia [19,20], a few study participants in those groups com-
plained of hypoglycemic symptoms; however, these complaints 
cannot be confirmed as true hypoglycemia, as our study did 
not involve self-monitoring of blood glucose levels at the time 
the study participants felt hypoglycemic symptoms. 
  The main adverse event with metformin was diarrhea; with 
rosiglitazone, it was edema due to fluid retention and weight 
gain. Overall, 8-12% of study participants experienced abdom-
inal disturbances including pain, discomfort, nausea, or vom-
iting during the study period; however, the symptoms were 
transient in the majority of the study participants and the caus-
al relationship between the study drugs and symptoms is un-
certain. We did not assess actual changes in lipid parameters 
during the study due to use of additional anti-hyperlipidemic 
agents. Lipid parameters are important in understanding sec-
ondary effects of the study drugs and are changeable according 
to the agents used [9,21]. Future studies should be designed to 
evaluate the true effects of antihyperglycemic agents on lipid 
parameters in Korean patients.
  In conclusion, this study demonstrates that the efficacies of 
glimepiride, metformin, and rosiglitazone are similar, with no 
statistical differences, when used for antidiabetic monothera-
py in drug-naïve type 2 diabetic patients. This trial is the first 
randomized controlled trial to evaluate the efficacy of com-
monly-used antidiabetic agents in Korean type 2 diabetic pa-
tients. Specific characteristics of the study drugs should be 
considered when choosing an appropriate agent. To use these 
results as valuable information for selecting an oral hypoglyce-
mic agent, more detailed subgroup analyses and further inves-
tigation is recommended.The efficacy of antidiabetic monotherapy in Korean
33 Diabetes Metab J 2011;35:26-33 http://e-dmj.org
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